These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11527734)

  • 1. Synthesis and bioactivities of novel 5,6-bis(4-methoxyphenyl)-2H-pyridazin-3-one derivatives: inhibitors of interleukin-1 beta (IL-1beta) production.
    Matsuda T; Aoki T; Koshi T; Ohkuchi M; Shigyo H
    Bioorg Med Chem Lett; 2001 Sep; 11(17):2373-5. PubMed ID: 11527734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and bioactivities of novel pyridazine derivatives: inhibitors of interleukin-1 beta (IL-1beta) production.
    Matsuda T; Aoki T; Ohgiya T; Koshi T; Ohkuchi M; Shigyo H
    Bioorg Med Chem Lett; 2001 Sep; 11(17):2369-72. PubMed ID: 11527733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-Substituted 4-, 5-, and 6-[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones and 2-substituted 4,5-bis[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones as potent platelet aggregation inhibitors: design, synthesis, and SAR studies.
    Meyers C; Yáñez M; Elmaatougi A; Verhelst T; Coelho A; Fraiz N; Lemière GL; García-Mera X; Laguna R; Cano E; Maes BU; Sotelo E
    Bioorg Med Chem Lett; 2008 Jan; 18(2):793-7. PubMed ID: 18053717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of substituted 6-pheny-3H-pyridazin-3-one derivatives as novel c-Met kinase inhibitors.
    Kang ST; Kim EY; Achary R; Jung H; Park CH; Yun CS; Hwang JY; Choi SU; Chae C; Lee CO; Kim HR; Ha JD; Ryu D; Cho SY
    Bioorg Med Chem Lett; 2014 Nov; 24(21):5093-7. PubMed ID: 25282552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and vasodilator activity of some pyridazin-3(2
    Allam HA; Kamel AA; El-Daly M; George RF
    Future Med Chem; 2020 Jan; 12(1):37-50. PubMed ID: 31710239
    [No Abstract]   [Full Text] [Related]  

  • 6. Design, synthesis, and structure-activity relationships of a novel series of 5-alkylidenepyridazin-3(2H)-ones with a non-cAMP-based antiplatelet activity.
    Coelho A; Raviña E; Fraiz N; Yáñez M; Laguna R; Cano E; Sotelo E
    J Med Chem; 2007 Dec; 50(26):6476-84. PubMed ID: 18031002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on the synthesis of condensed pyridazine derivatives. IV. Synthesis and anxiolytic activity of 2-aryl-5,6-dihydro-(1)benzothiepino[5,4- c]pyridazin-3(2H)-ones and related compound.
    Nakao T; Obata M; Kawakami M; Morita K; Tanaka H; Morimoto Y; Takehara S; Yakushiji T; Tahara T
    Chem Pharm Bull (Tokyo); 1991 Oct; 39(10):2556-63. PubMed ID: 1687209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners.
    Mylari BL; Armento SJ; Beebe DA; Conn EL; Coutcher JB; Dina MS; O'Gorman MT; Linhares MC; Martin WH; Oates PJ; Tess DA; Withbroe GJ; Zembrowski WJ
    J Med Chem; 2005 Oct; 48(20):6326-39. PubMed ID: 16190759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and Synthesis of Substituted Pyridazinone-1-Acetylhydrazones as Novel Phosphodiesterase 4 Inhibitors.
    Abdel-Rahman HM; Abdel-Aziz M; Tinsley HN; Gary BD; Canzoneri JC; Piazza GA
    Arch Pharm (Weinheim); 2016 Feb; 349(2):104-11. PubMed ID: 26686665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H₃ receptor antagonists.
    Tao M; Raddatz R; Aimone LD; Hudkins RL
    Bioorg Med Chem Lett; 2011 Oct; 21(20):6126-30. PubMed ID: 21906941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The synthesis and structure-activity relationship of pyridazinones as glucan synthase inhibitors.
    Ting PC; Kuang R; Wu H; Aslanian RG; Cao J; Kim DW; Lee JF; Schwerdt J; Zhou G; Wainhaus S; Black TA; Cacciapuoti A; McNicholas PM; Xu Y; Walker SS
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1819-22. PubMed ID: 21316223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SAR studies of pyridazinone derivatives as novel glucan synthase inhibitors.
    Zhou G; Ting PC; Aslanian R; Cao J; Kim DW; Kuang R; Lee JF; Schwerdt J; Wu H; Herr RJ; Zych AJ; Yang J; Lam S; Wainhaus S; Black TA; McNicholas PM; Xu Y; Walker SS
    Bioorg Med Chem Lett; 2011 May; 21(10):2890-3. PubMed ID: 21489787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and inhibition study of monoamine oxidase, indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase by 3,8-substituted 5H-indeno[1,2-c]pyridazin-5-one derivatives.
    Reniers J; Meinguet C; Moineaux L; Masereel B; Vincent SP; Frederick R; Wouters J
    Eur J Med Chem; 2011 Dec; 46(12):6104-11. PubMed ID: 22018876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and structure-activity relationship of 5-pyridazin-3-one phenoxypiperidines as potent, selective histamine H(3) receptor inverse agonists.
    Tao M; Aimone LD; Gruner JA; Mathiasen JR; Huang Z; Lyons J; Raddatz R; Hudkins RL
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1073-7. PubMed ID: 22197136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonism of interleukin-1 (IL-1)-induced uveitis with synthetic IL-1 blockers.
    Chiou GC; Chen Z; Xuan B; Yamasaki T; Okawara T
    J Ocul Pharmacol Ther; 1997 Oct; 13(5):427-33. PubMed ID: 9326724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and antiviral activity of novel pyridazines.
    Wang Z; Wang M; Yao X; Li Y; Tan J; Wang L; Qiao W; Geng Y; Liu Y; Wang Q
    Eur J Med Chem; 2012 Aug; 54():33-41. PubMed ID: 22608761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyridazines part 41: synthesis, antiplatelet activity and SAR of 2,4,6-substituted 5-(3-oxo-3-phenylprop-1-en-1-yl)- or 5-(3-phenylprop-2-enoyl)pyridazin-3(2H)-ones.
    Crespo A; Meyers C; Coelho A; Yáñez M; Fraiz N; Sotelo E; Maes BU; Laguna R; Cano E; Lemière GL; Raviña E
    Bioorg Med Chem Lett; 2006 Feb; 16(4):1080-3. PubMed ID: 16290144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 4,5-dihydropyridazin-3-one derivatives as histamine H₃ receptor inverse agonists.
    Hudkins RL; Aimone LD; Dandu RR; Dunn D; Gruner JA; Huang Z; Josef KA; Lyons JA; Mathiasen JR; Tao M; Zulli AL; Raddatz R
    Bioorg Med Chem Lett; 2012 Jan; 22(1):194-8. PubMed ID: 22142542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, enantioresolution, and activity profile of chiral 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones as potent N-formyl peptide receptor agonists.
    Cilibrizzi A; Schepetkin IA; Bartolucci G; Crocetti L; Dal Piaz V; Giovannoni MP; Graziano A; Kirpotina LN; Quinn MT; Vergelli C
    Bioorg Med Chem; 2012 Jun; 20(12):3781-92. PubMed ID: 22607879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of N-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1-3 (HIF PHD1-3) for the Treatment of Anemia.
    Debenham JS; Madsen-Duggan C; Clements MJ; Walsh TF; Kuethe JT; Reibarkh M; Salowe SP; Sonatore LM; Hajdu R; Milligan JA; Visco DM; Zhou D; Lingham RB; Stickens D; DeMartino JA; Tong X; Wolff M; Pang J; Miller RR; Sherer EC; Hale JJ
    J Med Chem; 2016 Dec; 59(24):11039-11049. PubMed ID: 28002958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.